AstraZeneca halts late-stage lung cancer trial; U.S. drug prices decline
AstraZeneca has discontinued a late-stage trial of a drug for metastatic non-small cell lung cancer, adding to a series of setbacks. Meanwhile, drug prices in the U.S. have been falling.
Related stories
Zipalertinib succeeds in Phase 3 trial for EGFR-mutant lung cancer, challenging Rybrevant · Cancer research
Regeneron secures approval for ultra-rare bone disorder drug · Drug development
This summary is AI-generated and original to Mobble; the linked article is the authoritative source.
Original headline: “STAT+: Pharmalittle: We’re reading about an AstraZeneca setback, falling U.S. drug prices, and more.” Browse more stories.